PharmAla Biotech Grants Jupiter Neurosciences Exclusive U.S. Rights to ALA-002 in $100M Licensing Deal

License Agreement Details and Financial Structure

On July 20, 2026, PharmAla Biotech announced the execution of a definitive license agreement with Jupiter Neurosciences. Jupiter gains an exclusive, perpetual, royalty-bearing license to develop, manufacture, and commercialize ALA-002 in the U.S., while PharmAla retains global rights outside the country.

The upfront payment includes US$1.5 million in cash and US$1.833 million in Jupiter common stock, which is subject to a 120-day lock-up and standard NASDAQ and U.S. securities regulations. Development and regulatory milestones can total up to US$23.33 million, with US$3.33 million payable upon first patient dosing in a Phase 3 trial and US$20 million upon FDA approval of a New Drug Application. Commercial milestones offer up to US$73.33 million, triggered by cumulative U.S. net sales reaching US$333.3 million, US$1 billion, and US$2 billion, resulting in payments of US$10 million, US$30 million, and US$33.3 million respectively. Following the third commercialization milestone, PharmAla will earn a 3% royalty on all U.S. net sales of licensed products.

Regulatory Status and Therapeutic Profile of ALA-002

ALA-002 is PharmAla's lead drug candidate, a patented, non-racemic MDMA formulation that has received FDA New Chemical Entity (NCE) designation. It is engineered to improve cardiovascular safety and reduce abuse liability compared to racemic MDMA, while retaining therapeutic benefits for neuropsychiatric disorders.

The company stresses that ALA-002 remains investigational and has not been approved by the FDA or other regulatory bodies. Its safety and efficacy have yet to be established, reflecting the early-stage development and inherent regulatory and clinical risks.

PharmAla’s Global Development Strategy and Rights Retention

A key feature of the agreement is PharmAla’s retention of all rights to ALA-002 outside the U.S., allowing independent international development and commercialization efforts. This enables PharmAla to focus resources on advancing ALA-002 and its broader MDXX pipeline globally while leveraging Jupiter’s U.S. expertise.

Will Avery, PharmAla’s CFO, described the licensing deal as a way to unlock value from ALA-002 without diluting the company’s stake in non-U.S. markets or shouldering the full cost of U.S. clinical development. The agreement’s development diligence provisions provide assurance that Jupiter will actively advance the asset.

Manufacturing and Supply Provisions

PharmAla commits to manufacturing and supplying GMP-grade ALA-002 drug product to Jupiter, though specific commercial terms for manufacturing and supply are to be negotiated separately. This dual role as licensor and manufacturer positions PharmAla to add value through supply agreements while maintaining production quality control.

PharmAla’s manufacturing capabilities are notable within the psychedelics sector, as it currently is the sole provider of clinical-grade MDMA for patient treatments outside clinical trials, demonstrating its regulatory and manufacturing expertise.

Jupiter Neurosciences’ CNS Pipeline Expansion

For Jupiter Neurosciences, acquiring exclusive U.S. rights to ALA-002 significantly expands its central nervous system (CNS) therapeutic portfolio. Jupiter’s lead asset, JOTROL, an enhanced-bioavailability resveratrol formulation, is in a Phase IIa trial for Parkinson’s disease. Adding ALA-002, a next-generation patented psychedelic NCE, diversifies Jupiter’s pipeline across neurodegeneration and neuropsychiatric disorder sectors.

Christer Rosén, Jupiter’s Chairman and CEO, described the transaction as a "high-conviction, strategically aligned" move enabling the company to manage two independent clinical-stage programs targeting areas with unmet patient needs. He acknowledged that both programs remain early-stage with significant clinical, regulatory, and financing risks.

Milestone Payment Conditions and Associated Risks

Contingent payments hinge on specific clinical, regulatory, and commercial milestones. Development and regulatory payments depend on first patient dosing in Phase 3 and FDA approval of a New Drug Application, both representing substantial hurdles. The company emphasized that milestone payments and royalties are contingent on achieving these events, which may not occur.

Commercial milestones are tied to cumulative U.S. net sales reaching US$333.3 million, US$1 billion, and US$2 billion, triggering payments of US$10 million, US$30 million, and US$33.3 million, respectively. Timing for these milestones depends on Jupiter’s success in development, commercialization, market adoption, competition, and regulatory timing—all uncertain at this stage.

PharmAla’s Positioning in Psychedelic Drug Development

PharmAla Biotech brands itself as a "regulatory first" company, emphasizing strong regulatory relationships as key to success in psychedelics. Its dual focus includes addressing the global shortage of clinical-grade MDMA for trials and commercial use, alongside developing novel MDXX class molecules.

The company has completed proof-of-concept research on several intellectual property families, including ALA-002, and markets LaNeo™—its proprietary MDMA product. The U.S. out-license of ALA-002 allows PharmAla to concentrate capital and operations on manufacturing and international clinical development while retaining ownership in most global markets.

Risks and Uncertainties Regarding Contingent Payments

The announcement contains detailed forward-looking statements outlining material risks, including potential failure to meet closing conditions, the investigational status of ALA-002, and the possibility that clinical trials may not confirm safety or efficacy. Other risks involve reliance on Jupiter and third parties, regulatory approval timing, drug scheduling, intellectual property challenges, competition, and market acceptance.

PharmAla explicitly states no assurance exists that milestone payments or royalties will be earned or that ALA-002 will receive approval or be commercialized. These disclaimers highlight the inherent uncertainties in biopharmaceutical development, where progression from investigational drug to approved therapy involves significant clinical, regulatory, and commercial risks. Investors should recognize that milestone and royalty payments depend on uncertain outcomes.

Intellectual Property and Market Differentiation

ALA-002’s FDA New Chemical Entity designation provides important intellectual property protection and regulatory advantages, typically granting extended exclusivity against generics post-approval. The patented non-racemic MDMA formulation distinguishes ALA-002 from racemic MDMA.

Designed to improve cardiovascular safety and reduce abuse potential compared to racemic MDMA, ALA-002 is positioned as a differentiated asset in the emerging psychedelics therapeutic space. Nonetheless, intellectual property protection, competitive dynamics, regulatory pathways, and market acceptance remain uncertain factors that could impact the asset’s value and commercial prospects.

Closing Conditions and Regulatory Outlook

The agreement was executed on July 20, 2026, though no specific closing date or full details on closing conditions were provided. PharmAla expects to receive the upfront payment and Jupiter common stock, which is subject to lock-up and regulatory restrictions. Forward-looking statements assume closing conditions will be met and that ALA-002 will progress through clinical and regulatory milestones.

Completion of the transaction depends on customary closing conditions, including regulatory approvals and third-party consents typical in pharmaceutical licensing deals. Investors should monitor for updates confirming transaction closing and any material changes to terms or conditions.